Q-omics provides the consensus-scored SDAD1P2 profile across patient tissues and cancer cell-line models. SDAD1P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, SDAD1P2 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, SDAD1P2 RNA expression shows 11,875 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ESCA, HNSC, and TGCT as cancer lineages where SDAD1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDAD1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDAD1P2 survival associations across molecular data types. SDAD1P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDAD1P2 RNA expression–survival associations across cancer types. High SDAD1P2 expression shows unfavorable associations in OV, BLCA and LIHC, but favorable associations in ESCA, UCS and LUSC. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify ESCA as the clearest survival context for SDAD1P2 RNA expression.
This table summarizes SDAD1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SDAD1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDAD1P2 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, CHOL, LUSC and LUAD. The HNSC box plot shows higher SDAD1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.722, t-test p < 0.001).
This table shows molecular features associated with SDAD1P2 in patient tissues and cancer cell lines. In patient samples, SDAD1P2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
